Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.

Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD.

Neurology. 2005 Dec 13;65(11):1716-22.

PMID:
16344512
2.

Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo.

Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich NJ, Heiss WD, Hilker R.

Neurology. 2010 Mar 16;74(11):885-92. doi: 10.1212/WNL.0b013e3181d55f61. Epub 2010 Feb 24.

PMID:
20181924
3.

Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.

Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, Ota T, Asahina M, Fukushi K, Kuwabara S, Hattori T, Suhara T, Irie T.

Neurology. 2009 Jul 28;73(4):273-8. doi: 10.1212/WNL.0b013e3181ab2b58. Epub 2009 May 27.

PMID:
19474411
4.

[(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.

Rinne OJ, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O.

Synapse. 2001 Jun 1;40(3):193-200.

PMID:
11304757
5.

Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.

Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T.

J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):155-63.

6.

Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.

Jokinen P, Brück A, Aalto S, Forsback S, Parkkola R, Rinne JO.

Parkinsonism Relat Disord. 2009 Feb;15(2):88-93. doi: 10.1016/j.parkreldis.2008.03.005. Epub 2008 Apr 22.

PMID:
18434233
8.

Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.

Brück A, Aalto S, Nurmi E, Bergman J, Rinne JO.

Neurobiol Aging. 2005 Jun;26(6):891-8.

PMID:
15718048
9.

Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.

Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O.

Arch Neurol. 2000 Apr;57(4):470-5.

PMID:
10768619
10.

[Cerebral glucose metabolism in Parkinson's disease with dementia].

Ma AJ, Zhang BS, Pan XD, Gao S, Li ZG.

Zhonghua Yi Xue Za Zhi. 2008 Oct 14;88(37):2623-8. Chinese.

PMID:
19080710
11.

[Evaluation of dopaminergic presynaptic function by [F-18] DOPA PET].

Kato T.

Rinsho Shinkeigaku. 2007 Nov;47(11):829-31. Japanese.

PMID:
18210809
12.

Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT.

Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1176-85. Epub 2005 Jun 2.

PMID:
15931516
13.

Function of sigma1 receptors in Parkinson's disease.

Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, Oda K, Sasaki T, Sakayori O, Hamamoto M, Kobayashi S, Katayama Y.

Acta Neurol Scand. 2005 Aug;112(2):103-7.

PMID:
16008536
14.

Striatal dopa and glucose metabolism in PD patients with freezing of gait.

Bartels AL, de Jong BM, Giladi N, Schaafsma JD, Maguire RP, Veenma L, Pruim J, Balash Y, Youdim MB, Leenders KL.

Mov Disord. 2006 Sep;21(9):1326-32.

PMID:
16721756
15.

Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.

Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, Brooks DJ.

Brain. 2002 Jun;125(Pt 6):1358-65. Erratum in: Brain 2002 Sep;125(Pt 9):2144.

16.

[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.

Jokinen P, Scheinin N, Aalto S, Någren K, Savisto N, Parkkola R, Rokka J, Haaparanta M, Röyttä M, Rinne JO.

Parkinsonism Relat Disord. 2010 Dec;16(10):666-70. doi: 10.1016/j.parkreldis.2010.08.021. Epub 2010 Sep 25.

PMID:
20870446
17.

Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease.

Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M.

Eur J Neurosci. 2007 May;25(10):3132-6.

PMID:
17561826
18.

Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.

Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE.

J Nucl Med. 1997 May;38(5):797-802.

19.

Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling.

Nagatsuka Si S, Fukushi K, Shinotoh H, Namba H, Iyo M, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T.

J Cereb Blood Flow Metab. 2001 Nov;21(11):1354-66.

20.

Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.

Kaasinen V, Maguire RP, Hundemer HP, Leenders KL.

J Neurol. 2006 Mar;253(3):340-8. Epub 2005 Oct 18.

PMID:
16222426
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk